Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia

Frontiers in Oncology

Volumn 1, Issue OCT, 2011, Pages

  Jovanovic, Jelena V ^a   Rennie, Kristian ^b   Culligan, Dominic ^c   Peniket, Andrew ^d   Lennard, Anne ^e   Harrison, Justin ^f   Vyas, Paresh ^g   Grimwade, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e ROYAL VICTORIA INFIRMARY   (United Kingdom)

^f Hemel Hempstead General Hospital   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acute myeloid leukemia; Minimal residual disease

Indexed keywords

EID: 84877292016     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00035     Document Type: Article

References (41)

1. Arnould, C., Philippe, C., Bourdon, V., Grégoire, M. J., Berger, R., and Jonveaux, P. (1999). The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum. Mol. Genet. 8, 1741-1749.
2. Beillard, E., Pallisgaard, N., van der Velden, V. H., Bi, W., Dee, R., van der Schoot, E., Delabesse, E., Macintyre, E., Gottardi, E., Saglio, G., Watzinger, F., Lion, T., van Dongen, J. J., Hokland, P., and Gabert, J. (2003). Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe Against Cancer program. Leukemia 17, 2474-2486.
3. Burnett, A. K., Grimwade, D., Solomon, E., Wheatley, K., and Goldstone, A. H. (1999). Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 93, 4131-4143.
4. Cahill, T. J., Chowdhury, O., Myerson, S. G., Ormerod, O., Herring, N., Grimwade, D., Littlewood, T., and Peniket, A. (2011). Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: diagnosis and follow-up by cardiac magnetic resonance imaging. Circulation 123, e370-e372.
5. Cassinat, B., Guillemot, I., Moluçon-Chabrot, C., Zassadowski, F., Fenaux, P., Tournilhac, O., and Chomienne, C. (2006). Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response. Haematologica 91(Suppl.), ECR58.
6. Catalano, A., Dawson, M. A., Somana, K., Opat, S., Schwarer, A., Campbell, L. J., and Iland, H. (2007). The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 110, 4073-4076.
7. Chen, Z., Brand, N. J., Chen, A., Chen, S. J., Tong, J. H., Wang, Z. Y., Waxman, S., and Zelent, A. (1993). Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12, 1161-1167.
8. Corbacioglu, A., Scholl, C., Schlenk, R. F., Eiwen, K., Du, J., Bullinger, L., Fröhling, S., Reimer, P., Rummel, M., Derigs, H. G., Nachbaur, D., Krauter, J., Ganser, A., Döhner, H., and Döhner, K. (2010). Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J. Clin. Oncol. 28, 3724-3729.
9. Culligan, D. J., Stevenson, D., Chee, Y. L., and Grimwade, D. (1998). Acute promyelocytic leukaemia with t(11;17)(q23;q12-21) and a good initial response to prolonged ATRA and combination chemotherapy. Br. J. Haematol. 100, 328-330.
10. Diverio, D., Rossi, V., Avvisati, G., De Santis, S., Pistilli, A., Pane, F., Saglio, G., Martinelli, G., Petti, M. C., Santoro, A., Pelicci, P. G., Mandelli, F., Biondi, A., and Lo-Coco, F. (1998). Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92, 784-789.
11. Dong, S., and Tweardy, D. J. (2002). Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 99, 2637-2646.
12. Esteve, J., Escoda, L., Martín, G., Rubio, V., Díaz-Mediavilla, J., González, M., Rivas, C., Alvarez, C., González San Miguel, J. D., Brunet, S., Tomás, J. F., Tormo, M., Sayas, M. J., Sánchez Godoy, P., Colomer, D., Bolufer, P., Sanz, M. A., Spanish Cooperative Group PETHEMA. (2007). Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 21, 446-452.
13. Flora, R., and Grimwade, D. (2004). Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML. Methods Mol. Med. 91, 151-173.
14. Freeman, S. D., Jovanovic, J. V., and Grimwade, D. (2008). Development of minimal residual disease directed therapy in acute myeloid leukemia. Semin. Oncol. 35, 388-400.
15. Gabert, J. A., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., Pane, F., Aerts, J. L., De Micheli, D., Thirion, X., Pradel, V., González, M., Viehmann, S., Malec, M., Saglio, G., and van Dongen, J. J. (2003). Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 17, 2318-2357.
16. Grimwade, D., Biondi, A., Mozziconacci, M.-J., Hagemeijer, A., Berger, R., Neat, M., Howe, K., Dastugue, N., Jansen, J., Radford-Weiss, I., Lo Coco, F., Lessard, M., Hernandez, J. M., Delabesse, E., Head, D., Liso, V., Sainty, D., Flandrin, G., Solomon, E., Birg, F., and Lafage-Pochitaloff, M. (2000). Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European working party. Blood 96, 1297-1308.
17. Grimwade, D., Gorman, P., Duprez, E., Howe, K., Langabeer, S., Oliver, F., Walker, H., Culligan, D., Waters, J., Pomfret, M., Goldstone, A., Burnett, A., Freemont, P., Sheer, D., and Solomon, E. (1997). Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90, 4876-4885.
18. Grimwade, D., Howe, K., Langabeer, S., Burnett, A., Goldstone, A., and Solomon, E. (1996). Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 10, 61-66.
19. Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, R. E., Solomon, E., Lo-Coco, F., Wheatley, K., and Burnett, A. K. (2009). Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J. Clin. Oncol. 27, 3650-3658.
20. Grimwade, D., Mistry, A. R., Solomon, E., and Guidez, F. (2010). Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat. Res. 145, 219-235.
21. Grimwade, D., and Tallman, M. S. (2011). Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk. Res. 35, 3-7.
22. Guidez, F., Parks, S., Wong, H., Jovanovic, J. V., Mays, A., Gilkes, A. F., Mills, K. I., Guillemin, M. C., Hobbs, R. M., Pandolfi, P. P., de Thé, H., Solomon, E., and Grimwade, D. (2007). RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 104, 18694-18699.
23. Iwanaga, E., Nakamura, M., Nanri, T., Kawakita, T., Horikawa, K., Mitsuya, H., and Asou, N. (2009). Acute promyelocytic leukemia harboring a STAT5B-RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B-RARA. Eur. J. Haematol. 83, 499-501.
24. Jurcic, J. G., Nimer, S. D., Scheinberg, D. A., DeBlasio, T., Warrell, R. P. Jr., and Miller, W. H. Jr. (2001). Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 98, 2651-2656.
25. Kishore, B., Stewart, A., Jovanovic, J., Craddock, C., and Grimwade, D. (2010). Arsenic trioxide and stem cell transplantation is an effective salvage therapy in patients with relapsed APL. Br. J. Haematol. 149(Suppl. 1), :22.
26. Kondo, T., Mori, A., Darmanin, S., Hashino, S., Tanaka, J., and Asaka, M. (2008). The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica 93, 1414-1416.
27. Krönke, J., Schlenk, R. F., Jensen, K. O., Tschürtz, F., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., Späth, D., Lübbert, M., Wattad, M., Kindler, T., Salih, H. R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H. G., Krauter, J., Ganser, A., Göhring, G., Schlegelberger, B., Döhner, H., and Döhner, K. (2011). Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J. Clin. Oncol. 29, 2709-2716.
28. Kusakabe, M., Suzukawa, K., Nanmoku, T., Obara, N., Okoshi, Y., Mukai, H. Y., Hasegawa, Y., Kojima, H., Kawakami, Y., Ninomiya, H., and Nagasawa, T. (2008). Detection of the STAT5B-RARA fusion transcript in acute promyelocytic leukemia with the normal chromosome 17 on G-banding. Eur. J. Haematol. 80, 444-447.
29. Licht, J. D., Chomienne, C., Goy, A., Chen, A., Scott, A. A., Head, D. R., Michaux, J. L., Wu, Y., DeBlasio, A., Miller, W. H. Jr., Zelenetz, A. D., Willman, C. L., Chen, Z., Chen, S.-J., Zelent, A., Macintyre, E., Veil, A., Cortes, J., Kantarjian, H., and Waxman, S. (1995). Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85, 1083-1094.
30. Lo Coco, F., Diverio, D., Avvisati, G., Petti, M. C., Meloni, G., Pogliani, E. M., Biondi, A., Rossi, G., Carlo-Stella, C., Selleri, C., Martino, B., Specchia, G., and Mandelli, F. (1999). Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94, 2225-2229.
31. Lo-Coco, F., Romano, A., Mengarelli, A., Diverio, D., Iori, A. P., Moleti, M. L., De Santis, S., Cerretti, R., Mandelli, F., and Arcese, W. (2003). Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 17, 1930-1933.
32. Mistry, A. R., Pedersen, E. W., Solomon, E., and Grimwade, D. (2003). The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 17, 71-97.
33. Mitelman, F., Johansson, B., and Mertens, F. (eds). (2011). Mitelman Database of Chromosome Aberrations, and Gene Fusions in Cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman
34. Ommen, H. B., Schnittger, S., Jovanovic, J. V., Ommen, I. B., Hasle, H., Østergaard, M., Grimwade, D., and Hokland, P. (2010). Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 115, 198-205.
35. Qiao, C., Zhang, S. J., Chen, L. J., Miao, K. R., Zhang, J. F., Wu, Y. J., Qiu, H. R., and Li, J. Y. (2011). Identification of the STAT5B-RARalpha fusion transcript in an acute promyelocytic leukemia patient without FLT3, NPM1, c-Kit and C/EBPalpha mutation. Eur. J. Haematol. 86, 442-446.
36. Redner, R. L., Rush, E. A., Faas, S., Rudert, W. A., and Corey, S. J. (1996). The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87, 882-886.
37. Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., Burnett, A. K., and Lo-Coco, F. (2009). Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113, 1875-1891.
38. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C., and Haferlach, T. (2009). Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114, 2220-2231.
39. Wells, R. A., Catzavelos, C., and Kamel-Reid, S. (1997). Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat. Genet. 17, 109-113.
40. Yamamoto, Y., Tsuzuki, S., Tsuzuki, M., Handa, K., Inaguma, Y., and Emi, N. (2010). BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood 116, 4274-4283.
41. Zhang, X. W., Yan, X. J., Zhou, Z. R., Yang, F. F., Wu, Z. Y., Sun, H. B., Liang, W. X., Song, A. X., Lallemand-Breitenbach, V., Jeanne, M., Zhang, Q. Y., Yang, H. Y., Huang, Q. H., Zhou, G. B., Tong, J. H., Zhang, Y., Wu, J. H., Hu, H. Y., de Thé, H., Chen, S. J., and Chen, Z. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240-243.